Trial Profile

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Dec 2016 According to a Hutchison MediPharma media release, data from this trial was presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals.
14 Nov 2016 Results published in the Chi Med Media Release
14 Nov 2016 Data from this trial will be presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals as reported by a Chi Med media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com